A metabolic enzyme best known for helping cells build the genetic material needed for growth has emerged as a potential weakness in lung adenocarcinoma, the most common major subtype of lung cancer. In a study published in the British Journal of Cancer, Xie, Xu, Zhou and colleagues report that cytidine triphosphate synthase 1, or CTPS1, is frequently increased in lung adenocarcinoma and contributes to the disease’s progression. Their work places a central nucleotide-producing enzyme at the intersection of cancer metabolism, tumour growth and therapeutic strategy, suggesting that CTPS1 may be more than a passive marker of rapidly dividing cells.
CTPS1 operates at a crucial point in the production of cytidine triphosphate, or CTP, one of the four ribonucleotide building blocks used to make RNA. CTP also feeds the production of deoxycytidine triphosphate, the DNA precursor required for genome duplication. The enzyme converts uridine triphosphate into CTP through a reaction that uses glutamine as a nitrogen source and consumes ATP. Because this reaction controls the availability of a key nucleotide, CTPS1 is considered rate-limiting: when its activity rises, the cell can increase the supply of molecular materials needed to copy its genome and sustain biosynthetic activity.
That function is particularly important in cancer. Malignant cells must repeatedly duplicate their DNA, manufacture large quantities of RNA and generate membranes and proteins while adapting to stressful conditions such as low oxygen, limited nutrients and immune pressure. Tumours can meet these demands by rewiring metabolism, diverting resources into pathways that support continuous proliferation. An increase in CTPS1 could therefore provide cancer cells with a practical advantage, helping them maintain nucleotide production even when normal metabolic regulation has been disrupted. The new study focuses on whether this advantage has a direct role in lung adenocarcinoma rather than merely reflecting the presence of rapidly dividing cells.
Lung adenocarcinoma develops from gland-forming epithelial cells in the lung and accounts for a substantial proportion of lung cancer diagnoses worldwide. Although targeted medicines have transformed treatment for patients whose tumours carry alterations in genes such as EGFR, ALK or ROS1, many tumours eventually become resistant, while other patients lack an actionable driver from the outset. This has increased interest in vulnerabilities that are shared across genetically diverse cancers. Metabolic dependencies are especially attractive because they may expose a tumour-wide requirement that persists even when its initiating mutation differs from that of another tumour.
The findings presented by the researchers identify CTPS1 as one such dependency in lung adenocarcinoma. The enzyme is described as frequently upregulated in tumour tissue, indicating that its increased presence is associated with the malignant state. More importantly, the study concludes that CTPS1 promotes lung adenocarcinoma progression. In biological terms, that means CTPS1 is linked not simply to the existence of cancer cells but to behaviours that allow the disease to advance. Those behaviours can include sustained proliferation, survival under stress and the capacity of tumour cells to expand within surrounding tissue, although the precise contribution of each process depends on the experimental systems used in the study.
The distinction between correlation and function is central to the significance of the report. Many genes become more active in cancer because cells are dividing quickly, and their elevated expression may be a consequence rather than a cause of disease. A functional metabolic enzyme becomes a therapeutic vulnerability when tumour cells depend on it sufficiently that reducing its activity impairs cancer growth more strongly than it harms normal tissues. By characterising CTPS1 as a targetable vulnerability, the researchers point toward an intervention strategy in which the enzyme or its supporting pathway is inhibited to restrict the nucleotide supply required by malignant cells.
Targeting CTPS1 would also illustrate the potential and the difficulty of attacking cancer metabolism. Normal cells use the same nucleotide pathways, so a successful treatment must exploit differences in demand, regulation or pathway flexibility between tumour and healthy tissue. Cancer cells may be unusually dependent on CTPS1 because of their high replication rate or because oncogenic signalling increases their need for CTP. They might also have less capacity to compensate through alternative routes. At the same time, systemic suppression of nucleotide production could affect healthy tissues that naturally divide rapidly, including bone marrow, intestinal lining and hair follicles. Selectivity, dosing and the ability to identify patients whose tumours are particularly dependent on CTPS1 will therefore be critical.
The biochemical position of CTPS1 makes it an appealing candidate for drug development, but translating a vulnerability into a medicine requires several steps. Investigators must establish whether inhibiting the enzyme blocks tumour growth in relevant models, determine how cancer cells respond over time and assess whether resistance emerges through altered nucleotide transport, activation of related enzymes or changes in nutrient use. The safety profile must be evaluated alongside evidence that the drug reaches lung tumours at effective concentrations. CTPS1 expression could eventually be examined as a biomarker, but expression alone may not predict dependence; functional activity, genomic context and the metabolic state of each tumour may also matter.
The study adds to a growing view of cancer as an ecological and biochemical system rather than a disease driven only by abnormal signalling genes. Lung adenocarcinoma cells must continually balance energy production, genome maintenance and adaptation to their environment. CTPS1 appears to occupy a critical point in that balance by connecting glutamine metabolism and energy use to the production of nucleotides. If future research confirms that this dependency can be blocked safely, CTPS1-directed therapy could complement existing targeted drugs, chemotherapy or immunotherapy. For now, the report provides a mechanistic rationale for investigating CTPS1 inhibition and highlights nucleotide biosynthesis as a promising frontier in the search for new treatments for lung adenocarcinoma.
Subject of Research: CTPS1 as a metabolic driver and targetable vulnerability in lung adenocarcinoma
Article Title: CTPS1 promotes lung adenocarcinoma progression as a targetable vulnerability
Article References: Xie, H., Xu, C., Zhou, B. et al. CTPS1 promotes lung adenocarcinoma progression as a targetable vulnerability. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03580-1
Image Credits: AI Generated
DOI: 10.1038/s41416-026-03580-1
Keywords: CTPS1, lung adenocarcinoma, cancer metabolism, nucleotide biosynthesis, CTP, tumour progression, targeted therapy, therapeutic vulnerability
